Development and challenges for T-cell engagers as a novel treatment for lung cancer and mesothelioma

Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC

MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer

Durvalumab plus chemotherapy improves survival in extensive-stage small cell lung cancer regardless of tumour laterality

Durvalumab improves survival and delays progression in limited-stage small cell lung cancer

Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung cancer

Pembrolizumab plus chemotherapy delivers lasting benefit in early-stage NSCLC

Becotarug plus osimertinib shows survival benefit in EGFR exon 20 insertion lung cancer

TQB2922 combination shows high response rates in EGFR-mutant lung cancer after tyrosine kinase inhibitor resistance

SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR-mutant lung cancer

Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant advanced lung cancer

Artificial intelligence PD-L1 scoring matches pathologists and improves reproducibility in lung cancer testing